Yasunori Suematsu

Dr. Yasunori Suematsu

Fukuoka University, Fukuoka, Japan
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 January 2016 in European Journal of Heart Failure
Verified
Journal Article
Open access
PDF file
YSYasunori Suematsu
Yasunori Suematsu
SMShin-ichiro Miura
Shin-ichiro Miura
MGMasaki Goto
Masaki Goto
YMYoshino Matsuo
Yoshino Matsuo
TATadaaki Arimura
Tadaaki Arimura
KSKeijiro Saku
Keijiro Saku
Aims Angiotensin receptor–neprilysin inhibitors (ARNis) acts an ARB and neprilysin inhibitor. Diabetes mellitus significantly increases the risk of cardiovascular disease and heart failure (HF). Therefore, we evaluated the effects and mechanisms of ARNi in HF with reduced ejection fraction (HFrEF) in streptozotocin-induced diabetic mice. Methods and results Male C57BL/6J mice were injected with streptozotocin to produce diabetic mice. After myocardial reperfusion injury, diabetic mice were randomized to treatment for 4 weeks with LCZ696 (60 mg/kg), valsartan (30 mg/kg), or no treatment (n = 26–28 in each group). Cardiac function was assessed by a pressure–volume Millar catheter. The ratios of heart weight to body weight in the valsartan (P = 0.02) and LCZ696 (P = 0.005) groups were significantly less than that in the control group. Treatment with LCZ696 improved LVEF (43 ± 3.4%) with a significantly reduction of atrial natriuretic peptide mRNA in the left ventricle compared with that in the control group (29 ± 3.2%) (P = 0.006). The fibrotic area in the LCZ696 group was significantly suppressed compared with those in the control (P = 0.003) and valsartan (P = 0.04) groups. Moreover, the mRNA level of transforming growth factor-β (TGF-β) in the left ventricle was suppressed in the LCZ696 group compared with that in the control (P = 0.002) group. Conclusion The ARNi LCZ696 improved cardiac function with the reduction of fibrosis in an HF-rEF model in diabetic mice, by suppressing TGF-β. This effect may be due to the specific inhibition of neprilysin, beyond the ARB effect of LCZ696.

1 April 2018 in Journal of Cardiac Failure
Verified
Journal Article
Closed access
YSYasunori Suematsu
Yasunori Suematsu
WJWanghui Jing
Wanghui Jing
ANAne C.F. Nunes
Ane C.F. Nunes
MKMoti L. Kashyap
Moti L. Kashyap
MKMahyar Khazaeli
Mahyar Khazaeli
HMHamid Moradi
Hamid Moradi

1 January 2014 in Circulation Journal
Verified
Journal Article
Open access
PDF file
KTKohei Takata
Kohei Takata
SISatoshi Imaizumi
Satoshi Imaizumi
EKEmi Kawachi
Emi Kawachi
YSYasunori Suematsu
Yasunori Suematsu
TSTomohiko Shimizu
Tomohiko Shimizu
KSKeijirio Saku
Keijirio Saku
Background:Smoking cessation reduces the risk of cardiovascular disease (CVD) and improves clinical outcomes in public health. We studied the effect of smoking cessation on high-density lipoprotein (HDL) functionality.Methods and Results:We randomly treated 32 smokers with varenicline or a transdermal nicotine patch as part of a 12-week smoking cessation program (The VN-SEESAW Study). The plasma lipid profiles, plasma and HDL malondialdehyde (MDA) levels, HDL subfractions as analyzed by capillary isotachophoresis, cholesterol efflux capacity, and antiinflammatory activity of HDL were measured before and after the anti-smoking intervention. After smoking cessation, HDL-C, apoA-I levels and HDL subfractions were not significantly different from the respective baseline values. However, cholesterol efflux capacity and the HDL inflammatory index (HII) were significantly improved after smoking cessation. The changes in both parameters (%∆ cholesterol efflux capacity and ∆HII) were also significantly improved in the successful smoking cessation group compared with the unsuccessful group. The changes in cholesterol efflux capacity and HII also correlated with those in end-expiratory CO concentration and MDA in HDL, respectively.Conclusions:Our findings indicate that smoking cessation leads to improved HDL functionality, increased cholesterol efflux capacity and decreased HII, without changing HDL-C or apoA-I levels or HDL subfractions. This may be one of the mechanisms by which smoking cessation improves the risk of CVD. (Circ J 2014; 78: 2955–2962)

15 December 2017
Verified
Journal Article
Closed access
WJWanghui Jing
Wanghui Jing
NVNosratola Vaziri
Nosratola Vaziri
ANAne C.F. Nunes
Ane C.F. Nunes
YSYasunori Suematsu
Yasunori Suematsu
TFTed Farzaneh
Ted Farzaneh
HMHamid Moradi
Hamid Moradi

1 December 2018 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Open access
PDF file
WLWei Ling Lau
Wei Ling Lau
NVNosratola D. Vaziri
Nosratola D. Vaziri
ANAne C.F. Nunes
Ane C.F. Nunes
ACAndré M. Comeau
André M. Comeau
MLMorgan G.I. Langille
Morgan G.I. Langille
KWKatrine L. Whiteson
Katrine L. Whiteson
In chronic kidney disease (CKD), the gut microbiome is altered and bacterial-derived uremic toxins promote systemic inflammation and cardiovascular disease. Ferric citrate complex is a dietary phosphate binder prescribed in end-stage kidney disease patients to treat hyperphosphatemia and secondary hyperparathyroidism. Iron is an essential nutrient in both microbes and mammals. The present study was undertaken to test the hypothesis that the large iron load administered with ferric citrate in CKD may significantly change the gut microbiome. Male Sprague Dawley rats underwent 5/6 nephrectomy to induce CKD. Normal control and CKD rats were randomized to regular chow or a 4% ferric citrate diet for 6 weeks. Fecal and cecal microbial DNA was analyzed via 16S rRNA gene sequencing on the Illumina MiSeq. CKD rats had lower abundances of Firmicutes and Lactobacillus compared to normal rats and had lower overall gut microbial diversity. CKD rats treated with ferric citrate had improved hemoglobin and creatinine clearance, and amelioration of hyperphosphatemia and hypertension. Ferric citrate treatment increased bacterial diversity in CKD rats almost to levels observed in control rats. The tryptophanase-possessing families Verrucomicrobia, Clostridiaceae and Enterobacteriaceae were increased by ferric citrate treatment. The uremic toxins indoxyl sulfate and p-cresyl sulfate were not increased with ferric citrate treatment. Verrucomicrobia was largely represented by Akkermansia muciniphila which has important roles in mucin degradation and gut barrier integrity. In summary, ferric citrate therapy in CKD rats was associated with significant changes in the gut microbiome and beneficial kidney and blood pressure parameters.

1 December 2014 in EuroIntervention
Verified
Journal Article
Closed access
YMYoshinobu Murasato
Yoshinobu Murasato
KIKiyotaka Iwasaki
Kiyotaka Iwasaki
TYTadashi Yamamoto
Tadashi Yamamoto
TYTakanobu Yagi
Takanobu Yagi
YHYutaka Hikichi
Yutaka Hikichi
TYTomohiko Yamamoto
Tomohiko Yamamoto
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)